At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period.

Here’s a table showing how ASX-listed healthcare stocks have been performing.

CODE COMPANY PRICE 1 WEEK RETURN % 6 MONTH RETURN % 1 YEAR RETURN % MARKET CAP
AT1 Atomo Diagnostics 0.255 46 34 -18 $ 85,824,970.77
ALT Analytica Limited 0.002 33 0 -33 $ 9,227,602.26
CDX Cardiex Limited 0.064 28 -18 25 $ 63,743,305.93
ADO Anteotech Ltd 0.25 25 -9 138 $ 434,289,766.24
DOC Doctor Care Anywhere 0.54 24 -35 -55 $ 107,466,636.91
OSL Oncosil Medical 0.044 16 -20 -65 $ 34,070,761.64
ICR Intelicare Holdings 0.09 15 -51 -63 $ 7,774,223.76
LDX Lumos Diagnostics 0.79 14 $ 105,383,784.10
CU6 Clarity Pharma 0.8 13 $ 124,088,685.75
GSS Genetic Signatures 1.52 13 35 -25 $ 211,782,444.08
RAC Race Oncology Ltd 3.65 13 1 103 $ 562,840,080.46
CGS Cogstate Ltd 2.59 13 88 135 $ 424,670,745.10
IHL Incannex Healthcare 0.565 12 131 277 $ 664,690,401.65
NOX Noxopharm Limited 0.38 12 -37 -22 $ 111,050,421.00
ACW Actinogen Medical 0.145 12 4 625 $ 244,041,406.81
BIT Biotron Limited 0.1 11 108 27 $ 65,279,742.31
CYP Cynata Therapeutics 0.5 11 -1 -29 $ 68,772,765.12
HXL Hexima 0.41 11 156 128 $ 63,322,865.20
OSP Osprey Med Inc 0.62 11 -56 -72 $ 14,753,661.65
IVX Invion Ltd 0.021 11 50 91 $ 134,746,786.52
MVF Monash IVF Group Ltd 1.09 10 28 40 $ 414,961,104.60
CTE Cryosite Limited 0.445 10 11 24 $ 21,720,255.54
RHY Rhythm Biosciences 1.62 9 76 101 $ 324,909,891.74
PGC Paragon Care Limited 0.355 9 37 48 $ 121,233,241.16
PAB Patrys Limited 0.038 9 -34 66 $ 74,042,010.32
IIQ Inoviq Ltd 1.165 8 -40 74 $ 105,821,507.30
PSQ Pacific Smiles Grp 2.89 8 5 18 $ 445,233,607.02
EYE Nova EYE Medical Ltd 0.33 8 5 -6 $ 45,121,675.21
NSB Neuroscientific 0.335 8 -1 34 $ 49,497,716.84
1ST 1St Group Ltd 0.014 8 -28 -58 $ 7,052,862.98
BWX BWX Limited 4.61 7 -15 15 $ 746,520,890.72
AHC Austco Healthcare 0.15 7 20 43 $ 42,628,342.65
TRP Tissue Repair 0.525 7 $ 23,655,453.25
AGH Althea Group 0.23 7 -28 -47 $ 71,859,135.29
VBS Vectus Biosystems 1.39 7 0 3 $ 45,078,216.87
PNV Polynovo Limited 1.545 7 -46 -61 $ 1,028,458,408.42
NYR Nyrada Inc. 0.235 7 -18 7 $ 28,267,654.81
AVE Avecho Biotech Ltd 0.016 7 -6 -43 $ 29,377,864.42
ZLD Zelira Therapeutics 0.032 7 -29 -65 $ 39,563,180.90
CPH Creso Pharma Ltd 0.081 7 -42 -55 $ 98,109,635.76
KZA Kazia Therapeutics 1.16 6 -11 -3 $ 151,842,790.35
RCE Recce Pharmaceutical 1.02 6 10 -3 $ 173,787,847.00
IPD Impedimed Limited 0.175 6 59 46 $ 310,767,187.85
ONE Oneview Healthcare 0.265 6 -42 489 $ 129,100,328.25
EZZ EZZ Life Science 0.54 6 15 $ 6,890,400.00
PCK Painchek Ltd 0.054 6 -11 -31 $ 61,117,459.15
ALC Alcidion Group Ltd 0.275 6 -33 56 $ 323,768,027.90
TRU Truscreen 0.074 6 21 $ 25,400,637.71
NTI Neurotech Intl 0.056 6 -5 40 $ 40,438,477.31
ANP Antisense Therapeut. 0.2 5 3 60 $ 133,717,354.80
DVL Dorsavi Ltd 0.02 5 -29 -44 $ 6,723,744.42
IRX Inhalerx Limited 0.081 5 -19 5 $ 13,477,356.56
UBI Universal Biosensors 0.925 5 16 115 $ 160,045,653.60
DXB Dimerix Ltd 0.24 4 17 0 $ 78,614,048.17
OPT Opthea Limited 1.325 4 1 -32 $ 466,319,546.00
ILA Island Pharma 0.27 4 -8 $ 11,027,007.33
BDX Bcaldiagnostics 0.135 4 $ 18,413,718.68
CBL Control Bionics 0.415 4 -39 -58 $ 20,887,325.99
AN1 Anagenics Limited 0.058 4 -3 -46 $ 12,552,394.37
CAN Cann Group Ltd 0.29 4 -18 -45 $ 102,912,078.39
RSH Respiri Limited 0.059 4 -17 -55 $ 41,924,765.82
IMM Immutep Ltd 0.495 3 -6 27 $ 427,061,400.50
VHT Volpara Health Tech 1.015 3 -13 -28 $ 256,490,302.62
OCC Orthocell Limited 0.51 3 -14 16 $ 100,520,537.43
CHM Chimeric Therapeutic 0.2675 3 -8 $ 56,196,215.07
4DX 4Dmedical Limited 1.255 3 7 -49 $ 265,373,819.01
ALA Arovella Therapeutic 0.037 3 -33 -3 $ 17,794,072.56
SDI SDI Limited 1.0325 3 13 31 $ 122,431,495.90
TD1 Tali Digital Limited 0.019 3 -41 -62 $ 16,774,304.20
RGS Regeneus Ltd 0.077 3 3 -41 $ 23,595,642.38
NC6 Nanollose Limited 0.1025 3 11 90 $ 14,888,636.80
MX1 Micro-X Limited 0.265 2 -17 -26 $ 119,633,213.70
IMU Imugene Limited 0.4275 2 16 328 $ 2,390,348,688.99
RNO Rhinomed Ltd 0.29 2 87 76 $ 71,447,511.30
HGV Hygrovest Limited 0.058 2 -27 -52 $ 14,027,193.09
RAP Resapp Health Ltd 0.061 2 49 -24 $ 50,692,627.54
PAR Paradigm Bio. 1.92 2 -1 -23 $ 443,811,800.25
PBP Probiotec Limited 2.25 1 0 -3 $ 182,977,663.50
CYC Cyclopharm Limited 1.615 1 -7 -37 $ 152,200,961.49
PAA Pharmaust Limited 0.092 1 0 -16 $ 30,106,676.39
NEU Neuren Pharmaceut. 3.91 1 151 201 $ 457,255,403.88
LBT LBT Innovations 0.098 1 21 -18 $ 26,309,479.92
PIQ Proteomics Int Lab 1.14 1 23 48 $ 120,447,697.50
MVP Medical Developments 5.22 1 12 -22 $ 372,794,698.11
CAJ Capitol Health 0.3675 1 4 34 $ 385,620,479.44
BXN Bioxyne Ltd 0.026 0 -13 117 $ 16,643,780.35
VLS Vita Life Sciences.. 1.93 0 86 99 $ 101,619,541.16
PXS Pharmaxis Ltd 0.11 0 47 26 $ 57,636,932.12
SHG Singular Health 0.29 0 -9 $ 18,761,109.78
NXS Next Science Limited 1.22 0 -15 -5 $ 243,507,908.07
ICS ICSGlobal Limited 0.575313 0 0 3 $ 6,054,604.94
SCU Stemcell United Ltd 0.014 0 -7 -22 $ 14,606,489.21
ADR Adherium Ltd 0.011 0 -35 -61 $ 24,240,364.95
RAD Radiopharm 0.37 0 $ 42,583,449.16
RAD Radiopharm 0.37 0 $ 42,583,449.16
JTL Jayex Technology Ltd 0.021 0 -25 -49 $ 5,233,799.32
SOM SomnoMed Limited 2.22 0 1 9 $ 183,725,679.30
FFC Farmaforce Ltd 0.046 0 -36 -49 $ 6,011,325.08
S66 Star Combo 0.255 0 2 -18 $ 34,298,260.16
ACR Acrux Limited 0.1 0 -20 -39 $ 28,368,033.80
RHT Resonance Health 0.1 0 -38 -57 $ 46,085,198.10
BPH BPH Energy Ltd 0.037 0 -49 9 $ 24,602,017.39
ATX Amplia Therapeutics 0.155 0 -32 -32 $ 31,985,910.17
OVN Oventus Medical Ltd 0.08 0 -13 -64 $ 19,096,396.27
GTG Genetic Technologies 0.005 0 -44 -29 $ 50,786,808.29
AMT Allegra Orthopaedics 0.15 0 -25 -55 $ 15,668,880.45
PAL Palla Pharma Ltd 0.295 0 -20 -59 $ 47,764,383.09
LCT Living Cell Tech. 0.005 0 -56 -63 $ 5,899,234.12
MEB Medibio Limited 0.005 0 -29 -44 $ 10,305,255.62
EPN Epsilon Healthcare 0.075 0 -42 -68 $ 17,148,435.07
ARX Aroa Biosurgery 1.015 -1 -4 -8 $ 349,142,055.66
AC8 Auscann Grp Hlgs Ltd 0.082 -1 -18 -54 $ 37,446,504.35
ZNO Zoono Group Ltd 0.37 -1 -40 -72 $ 62,818,828.66
MXC Mgc Pharmaceuticals 0.0365 -1 -1 46 $ 102,545,622.30
IBX Imagion Biosys Ltd 0.071 -1 -29 -47 $ 80,713,334.45
MDC Medlab Clinical Ltd 0.1425 -2 -5 -41 $ 49,615,472.30
PTX Prescient Ltd 0.23 -2 12 259 $ 143,020,505.10
HCT Holista CollTech Ltd 0.045 -2 -30 -38 $ 12,666,058.00
1AD Adalta Limited 0.082 -2 -36 -34 $ 24,355,214.09
M7T Mach7 Tech Limited 0.81 -2 -23 -32 $ 192,201,700.50
CMP Compumedics Limited 0.38 -3 6 -23 $ 68,207,734.98
TLX Telix Pharmaceutical 7.85 -3 33 101 $ 2,246,374,515.04
BOT Botanix Pharma Ltd 0.057 -3 -31 -50 $ 53,522,814.07
IDT IDT Australia Ltd 0.28 -3 -15 51 $ 67,160,847.60
PYC PYC Therapeutics 0.135 -4 -10 -7 $ 445,329,654.42
MDR Medadvisor Limited 0.36 -4 22 0 $ 136,035,310.32
EXL Elixinol Wellness 0.072 -4 -45 -60 $ 23,377,427.02
MEM Memphasys Ltd 0.09 -4 38 -10 $ 71,296,050.33
OSX Osteopore Limited 0.22 -4 -53 -58 $ 25,799,012.36
ATH Alterity Therap Ltd 0.021 -5 -25 -34 $ 50,544,366.14
VTI Vision Tech Inc 0.885 -5 -20 -62 $ 20,917,417.50
OIL Optiscan Imaging 0.17 -6 -26 48 $ 105,261,552.34
TSN The Sust Nutri Grp 0.21 -7 -43 -36 $ 26,533,404.70
BNO Bionomics Limited 0.11 -8 -42 -21 $ 137,503,458.12
GLH Global Health Ltd 0.335 -12 -29 -23 $ 19,813,287.20
IMC Immuron Limited 0.1 -13 -38 -57 $ 25,057,818.06

 

Biggest winners for the week

Atomo Diagnostics (ASX:AT1) was the best performing healthcare stock this week, as the Omicron variant continues to rage across Australia particularly in NSW and VIC.

Atomo provides rapid testing products and benefits from COVID testing.

Rapid testing has only been permitted by the TGA in recent months, and Atomo is one such provider. After selling less than 5,000 units in all of FY21, it sold 100,000 units in the September quarter alone.

Blood pressure specialist CardieX Limited (ASX:CDX) is up by more than 30% for the week on no particular news.

The stock has however been riding on a “speculative buy” recommendation initiated by a leading independent analyst, Blue Ocean Equities.

Blue Ocean has put a target price on CDX at 16c vs the current share price of 6.5c.

The analysts pointed to CDX early-stage growth potential, and the impending nature of the FDA clearance process for its new product suite as the main reasons for the buy recommendation.

Among the suite of products CardieX is developing is a “dual blood pressure monitor” – the “CONNEQT Pulse” – which is anticipated to be the world’s first consumer vital signs monitor to include central blood pressure and other advanced arterial health biometrics.

OncoSil Medical (ASX:OSL) surged after releasing the final results of the PanCO clinical study for the treatment of advanced pancreatic cancer.

The full paper was published in ESMO Open, the European Society for Medical Oncology’s peer-reviewed journal dedicated to publishing high-quality medical research.

Conducted at ten specialist centres in Australia, Belgium and the UK, the study demonstrated that lead drug OncoSil had an acceptable safety profile when added to standard-of-care chemotherapy.
 

Biggest losers for the week

Immuron (ASX:IMC) has been one the worst performers over the past week, despite new data showing that its lead product, IMM124E, had potential antiviral benefits.

The study of IMM124E showed that it could boost immunity across viral strains, including the SARS-2 virus that causes COVID-19 disease.

The company is also collaborating with the US Department of Defence to initiate a clinical trial program to study Travelan, a dietary supplement product to treat diarrhoea.

Bionomics (ASX:BNO) dropped after announcing the completion of an IPO in the US in which it raised around US$20m.

The new 1,622,000 American Depositary Shares (ADS) started trading on the Nasdaq Global Market on December 16, under the ticker symbol “BNOX”.

 

Other notable ASX healthcare news

Neuroscientific Biopharma (ASX:NSB) released positive results from the recently completed off-target safety assessment of its lead drug candidate, EmtinB.

Off-target safety assessments help to identify unintended interactions between a drug and a host of biological targets that are known to cause adverse side effects and toxicities in humans.

The assessment involved a comprehensive in-vitro screening program prior to the first in-human Phase I clinical study, which is expected to commence in the first half of 2022.

Cell therapy specialist, Cynata Therapeutics (ASX:CYP), has signed an agreement with FujiFilm Cellular Dynamics (FCDI) to manufacture Cynata’s Cymerus therapeutic mesenchymal stem cell (MSC) products.

According to CEO Dr Ross Macdonald, who spoke to Stockhead recently, MSC is the hottest segment of stem cell therapy at the moment.

In short, MSC therapies work by expressing a variety of chemokines and cytokines that aid in repair of degraded tissue, and counteract inflammation. Because MSCs play a co-ordination role within the immune system, they can be used to treat different diseases.

Currently, the biggest problem facing MSC-based therapies is how to manufacture these products on a mass scale, according to Dr  McDonald.